Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.41 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8053435 | 0.94 | ADAM17 (0.45) | ADAM17EPHX2TSHRALDH1A1CYP3A4 | |
| Hydrochloric Acid SCHEMBL8049068 | 0.93 | ADAM17 (0.44) | ADAM17EPHX2TSHRALDH1A1CYP3A4 | |
| SCHEMBL8049066 | 0.92 | EPHX2 (0.44) | ADAM17EPHX2TSHRALDH1A1CYP3A4 | |
| SCHEMBL8050802 | 0.92 | ADAM17 (0.43) | ADAM17EPHX2TSHRALDH1A1CYP3A4 | |
| SCHEMBL8536152 | 0.89 | OPRM1 (0.47) | ADAM17EPHX2ALDH1A1LMNAOPRM1 | |
| SCHEMBL15927866 | 0.87 | ADAM17 (0.46) | ADAM17EPHX2TSHRALDH1A1CYP3A4 | |
| SCHEMBL12277199 | 0.86 | LMNA (0.46) | ADAM17EPHX2TSHRALDH1A1CYP3A4 | |
| SCHEMBL15306513 | 0.86 | ADAM17 (0.45) | ADAM17EPHX2TSHRALDH1A1CYP3A4 | |
| SCHEMBL297404 | 0.86 | ADAM17 (0.45) | ADAM17EPHX2TSHRALDH1A1CYP3A4 | |
| SCHEMBL19348564 | 0.85 | ADAM17 (0.44) | ADAM17EPHX2TSHRALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4558493-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE | Iambic Therapeutics, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| US-20240092761-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS, INC. | 2024-03-21 | — | — | US | disclosed |
| WO-2024020380-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2024020380-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| CN-114057739-A | Diazepinone derivatives and their use in the treatment of hepatitis b infections | 诺维拉治疗公司 | 2022-02-18 | — | — | CN | disclosed |
| US-11161837-B2 | Benzofuran derivatives for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-11-02 | — | — | US | disclosed |
| US-11161837-B2 | Benzofuran derivatives for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-11-02 | — | — | US | disclosed |
| CN-109641896-B | Diazepinone derivatives and their use in the treatment of hepatitis b infections | 诺维拉治疗公司 | 2021-09-21 | — | — | CN | disclosed |
| EP-3478683-B1 | DIAZEPINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS INC (US) | 2021-07-21 | — | — | EP | disclosed |
| US-20210188849-A1 | DIAZEPINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS INC (US) | 2021-06-24 | — | — | US | disclosed |
| US-6080750-A | FOR PROPHYLAXIS AND TREATMENT OF DISEASES CAUSED BY INFECTION BY ROTAVIRUS | NIPPON SHOJI KAISHA LTD. (JP) | 2000-06-27 | — | — | US | disclosed |
| US-6001841-A | ANTISENSE DIAGNOSTICS, THERAPEUTICS AND RESEARCH REAGENTS. | ISIS PHARMACEUTICALS, INC. (US) | 1999-12-14 | — | — | US | disclosed |
| US-5817776-A | TECHNETIUM 99 COMPLEXES, SINGLE PHOTON EMISSION TOMOGRAPHY | EMORY UNIVERSITY (US) | 1998-10-06 | — | — | US | disclosed |
| US-5808146-A | Amino acid analogs for tumor imaging | EMORY UNIVERSITY (US) | 1998-09-15 | — | — | US | disclosed |
| EP-0862464-A1 | AMINO ACID ANALOGS FOR TUMOR IMAGING | EMORY UNIVERSITY (US) | 1998-09-09 | — | — | EP | disclosed |
| EP-0806418-A2 | Novel pyrimidine compound and anti-rotavirus agent | NIPPON SHOJI KAISHA, LIMITED (JP) | 1997-11-12 | — | — | EP | disclosed |
| WO-1997017092-A1 | AMINO ACID ANALOGS FOR TUMOR IMAGING | EMORY UNIVERSITY (US) | 1997-05-15 | — | — | WO | disclosed |
| EP-0689460-A1 | CYCLOBUTYL ANTISENSE OLIGONUCLEOTIDES, METHODS OF MAKING AND USE THEREOF | ISIS PHARMACEUTICALS, INC. (US) | 1996-01-03 | — | — | EP | disclosed |
| US-5359044-A | Diagnosis, chemical intermediates | ISIS PHARMACEUTICALS (US) | 1994-10-25 | — | — | US | disclosed |
| WO-1994019023-A1 | CYCLOBUTYL ANTISENSE OLIGONUCLEOTIDES, METHODS OF MAKING AND USE THEREOF | ISIS PHARMACEUTICALS, INC. (US) | 1994-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092761-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE | CCNI, CDK3, CDK1 | ADAM17 4118/4885EPHX2 3169/4885TSHR 2844/4885 |
| US-20210188849-A1 | DIAZEPINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF HEPATITIS B INFECTIONS | HAVCR2, NR1H4, NR1H2 | ADAM17 713/4885EPHX2 1724/4885TSHR 3120/4885 |
| US-11161837-B2 | Benzofuran derivatives for the treatment of hepatitis C | HAVCR2, UGT2B7, GOT1 | ADAM17 4132/4885EPHX2 3408/4885TSHR 4496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.